Haemostatic risk factors in healthy postmenopausal women taking hormone replacement therapy

Maturitas

Volumn 43, Issue 2, 2002, Pages 125-133

  Norris, L A ^a   Joyce, M ^a   O'Keeffe, N ^a   Sheppard, B L ^a   Bonnar, J ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Haemostatic risk factors; Hormone replacement therapy; Postmenopausal

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 7; D DIMER; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; FIBRINOGEN; FRUCTOSE BISPHOSPHATE; NORETHISTERONE ACETATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ANTITHROMBIN COMPLEX; TIBOLONE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG SYNTHESIS; FEMALE; FIBRIN METABOLISM; FIBRINOLYSIS; HEART PROTECTION; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; PROTEIN DETERMINATION; RISK FACTOR; THROMBOEMBOLISM; VEIN THROMBOSIS;

ESTRADIOL; FEMALE; HEMOSTASIS; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; NORETHINDRONE; NORPREGNENES; POSTMENOPAUSE; RISK FACTORS; TIME FACTORS;

EID: 0037174902     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(02)00202-5     Document Type: Article

References (43)

1. Kannel W.B., Hortland M.C., McNamara P.M., Gordon T. Menopause and the risk of cardiovascular disease. Ann. Intern. Med. 85:1976;447-452.
2. Colditz G.A., Willet W.C., Stampfer M.J., Rooner B., Speizer F.E., et al. Menopause and the risk of coronary heart disease. N. Engl. J. Med. 316:1987;1105-1110.
3. Scarabin P.-Y., Plu-Bureau G., Bara L., Bonithon-Kopp C., Guize L., Samama M.M. Haemostatic variables and menopausal status: influence of hormone replacement therapy. Thromb. Haemost. 70:(4):1993;584-587.
4. Grodstein F., Stampfer M.J., Colditz G.A., Willet W.C., Manson J.E., Joffe M., et al. Post menopausal hormone therapy and mortality. N. Engl. J. Med. 336:1997;1383-1389.
5. Wolf P.H., Madans J.H., Finucane F.F., Higgins M., Kleinman J.C. Reduction of cardiovascular disease related mortality among post menopausal women who use hormones: evidence from a national cohort. Am. J. Obstet. Gynecol. 164:1991;489-494.
6. The writing going of for the PEPI trial. Effect of estrogen/progestin regimens on heart disease risk factors in post menopausal women: the post-menopausal estrogen/progestin interventions (PEPI) trial. J Am Med Assoc (1995) 273: 199-2008.
7. Hulley S., Grady D., Bush T., et al. Randomised trial of estrogen plus progestin in the secondary prevention of coronary heart disease in post menopausal women. J. Am. Med. Assoc. 280:1998;605-613.
8. Herrington D.M., Reboussin D.M., Brosnihan K.B., Sharp P.C., Shumarker S.A., Snyder T.E. Effects of estrogen replacement on the progression of atherosclerosis. N. Engl. J. Med. 343:2000;522-529.
9. Daly E., Vessey M.P., Hawkins M.M., Carson J.L., Gough P., Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 348:1996;977-980.
10. Hoibraten E., Abdelnoor M., Morten Dandset P.M. Hormone replacement therapy with estradiol and risk of venous thromboembolism. Thromb. Haemost. 82:1999;1218-1221.
11. Lowe G., Woodward M., Vessey M., Rumley A., Gough P., Daly E. Thrombotic variables and the risk of idiopathic venous thromboembolism in women aged 45-64 years: relationships to hormone replacement therapy. Thromb. Haemost. 83:2000;530-535.
12. Teede H.J., McGrath B.P., Smolich J.J., Malan E., Kotsoupoulos D., Liang Y.-L., Peverill R.E. Post menopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler. Thromb. Vasc. Biol. 20:2000;1404-1409.
13. Crosigniani P.G., La Vecchia C. Concordant and discordant effects on cardiovascular risks exerted by oestrogen and progestogen in women using oral contraception hormone replacement therapy. Hum. Reprod. Update. 5:(6):1999;681-687.
14. Scarabin P.Y., Alhene-Gelas M., Plu-Bureau G., Taisne P., Agher R., Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in post menopausal women: a randomised controlled trial. Arterioscler. Thromb. Vasc. Biol. 17:(11):1997;3071-3078.
15. Caine Y.G., Bauer K.A., Barzegar S., ten Cate H., Sacks F.M., Walsh B.W., Rosenberg R.D. Coagulation activation following estrogen administration to post menopausal women. Thromb. Haemost. 68:(4):1992;392-395.
16. Crook D. The metabolic consequences of treating post menopausal women with non oral hormone replacement therapy, Br J Obstet Gynecol 1997;104(Suppl. 16):4-13.
17. Giddings J.C. Heriditary coagulation disorders. Laboratory techniques. Thomson J.M., A practical guide to blood coagulation and haemostasis. 1980;117 Churchill Livingstone, London.
18. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmumg des Fibrinogens. Acta Haematol. 17:1957;237-246.
19. Ranby M., Norrman B., Wallen P. A sensitive assay for tissue plasminogen activator. Thromb. Res. 27:1982;743-749.
20. DeClerk PJ, Alessi MC, Verstreken M, Kruithof EKO, Juhan-Vague I, Collen D. Measurement of plasminogen activator inihibitor I in biologic fluids with a murine monoclonal antibody-based enzyme linked immunosorbent assay, Blood (1988) 71: 220-225.
21. Bergsdorf N., Nilsson T., Wallen P. An enzyme linked immunosorbent assay for determination of tissue plasminogen activator applied to patients with thromboembolic disease. Thromb. Haemost. 50:1983;740-745.
22. Koppert P.W., Hoegee-de Nobel E., Nieuwenhuizen W. A monoclonal antibody based enzyme immunoassay for fibrin degradation products in plasma. Thromb. Haemost. 59:1988;310-315.
23. Pelzer H., Schwarz A., Heimburger N. Determination of human thrombin-antithrombin complex in plasma with enzyme linked immunosorbent assay. Thromb. Haemost. 59:1988;101-106.
24. Kannel W.B., Wolf P.A., Castelli W.P., D'Aquistino R.B. Fibrinogen and the risk of cardiovascular disease: the Framingham study. J. Am. Med. Assoc. 258:1987;1183-1186.
25. Meade T.W., Ruddock V., Stirling Y., Chakrabarly R., Miller G.J. Fibrinolytic activity, clotting factors and long term incidence of isehaemic heart disease in the Northwick Part Heart Study. Lancet. 342:1993;1076-1079.
26. Reiner A.P., Siscovick D.S., Rosendaal F.R. Hemostatic risk factors and arterial thrombotic disease. Thromb. Haemost. 85:2001;584-595.
27. Andersen L.F., Gram J., Skouby S.O., Jespersen J. Effects of hormone replacement therapy on hemostatic cardiovascular risk factors. Am. J. Obstet. Gynecol. 180:1999;283-289.
28. Winkler U.H., Altkemper R., Kwee B., Helmond F.A., Bennink H.J.T.C. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double blind, randomised study. Fertil. Steril. 74:(1):2000;10-18.
29. The Writing Group for the Estradiol Clotting Factors Study . Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1 year double blind placebo controlled study. Thromb. Haemost. 75:(3):1996;476-480.
30. Nabulsi A.A., Folsom A.R., White A., Patsch W., Heiss C., Wu K.K., et al. Association of hormone replacement therapy with various cardiovascular risk factors in post menopausal women. N. Engl. J. Med. 328:1993;1069-1075.
31. van Baal M.W., Emeis J.J., Van der Mooren M.J., Kessel H., Kenemans P., Stehouwer C.D.A. Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised placebo-controlled 12 week study. Thromb. Haemost. 83:2000;29-34.
32. Vehkavaara S., Silveira A., Hakala-Ala-Pietala T., Virkamaki A., Hovatta O., Hamsten A., Taskinen M.-J., Yki-Jarvinen H. Effects of oral and transdermal estrogen replacement on makers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in post menopausal women. Thromb. Haemost. 85:2001;619-625.
33. Kroon U.-B., Silfverstolpe G., Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostatic variables. Thromb. Haemost. 71:(4):1994;420-423.
34. Milner M.H., Sinnot M.M., Cooke T.M., Kelly A., McGill T., Harrison R.F. A 2 year study of lipid and lipoprotein changes in post menopausal women with tibolone and estrogen-progestin. Obstet. Gynecol. 87:1996;593-599.
35. Martinelli I. Risk factors in venous thromboembolism. Thromb. Haemost. 86:2001;395-403.
36. Zoller B., Dahlback B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet. 343:1994;1536-1538.
37. Hoibraaten E., Mowinkel M.C., De Ronde I.I., Bertina R.M., Sandset P.M. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomised double blind placebo controlled trial. Br. J. Haematol. 115:2001;415-420.
38. Wells M.J., Sheffield W.P., Blajchman M.A. The clearance of thrombin-antithrombin and related serpin enzyme complexes from the circulation: role of various hepatocyte receptors. Thromb. Haemost. 81:(3):1999;335-337.
39. Koh K.K., Horne M.K., Cannon R.O. Effects of hormone replacement therapy on coagulation, fibrinolysis and thrombosis risk in post menopausal women. Thromb. Haemost. 82:(2):1999;626-633.
40. Shahar F., Folsom A.R., Salomaa V.V., Stinson V.L., McGovern P.G., Shimakawa T., Chambless L.E., Wu K.K. Relation of hormone replacement therapy to measures of plasma fibrinolytic activity. Circulation. 93:1996;1970-1975.
41. Juhan-Vague L., Alessi M.C. Plasminogen activator inihibitor and atherothrombosis. Thromb. Haemost. 70:1993;138-143.
42. Lopez Y., Paloma M.J., Rifon J., Cuesta B., Paramo J.A. Measurement of prothrombic markers in the assessment of acquired hypercoagulable states. Thromb. Res. 93:1999;71-78.
43. Mosca L., Collins P., Herrington D.M., Mendelsohn M.E., Pasternak R.C., Robertson R.M., et al. Hormone replacement therapy and cardiovascular disease. A statement for healthcare professionals from the American heart association. Circulation. 104:2001;499-503.